Prior studies with shorter follow-up have suggested that diabetes may not confer additional myocardial infarction (MI) risk in patients without coronary artery disease (CAD) as confirmed by coronary angiography - suggesting that CAD, rather than diabetes alone, drives MI risk in patients with diabetes.
To...
A. Odgaard, C. Gyldenkerne, N. Sattar et al.· European Heart Journal· 0 citations
Abstract Background The nomenclature change from non-alcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease (MASLD) better encapsulates the associated metabolic milieu. While MASLD is associated with increased heart failure (HF) risk, characteristics and outcomes of MASLD in patients...
N. Chew, Chandramouli Chanchal, W. Tay et al.· Open Heart· 0 citations
AIMS
The impact of tirzepatide and dulaglutide on major adverse cardiovascular events (MACE) and heart failure (HF) outcomes according to HF status is unknown.
METHODS AND RESULTS
Patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease were treated with tirzepatide up to 15 mg or dulaglutide 1....
S. J. Nicholls, I. Pavo, Deepak L. Bhatt et al.· European Journal of Preventi...· 0 citations
Younger age at type 1 diabetes diagnosis is associated with greater risk of mortality and complications, with each additional year delay in onset being significantly associated with lower risk.
A. Rawshani, Björn Eliasson, Darren K. McGuire et al.· Diabetes Care· 0 citations
BACKGROUND
Heart failure (HF) is a common cardiovascular complication of diabetes. Early identification of unrecognized HF enables initiation of disease-modifying therapies. International diabetes and HF clinical practice guidelines are inconsistent with respect to recommendations for screening for HF in people with di...
D. Taylor-Sweet, M. Petrie, Gemma Mckinley et al.· Journal of the American Coll...· 1 citation
To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D).
G. Ruotolo, C. Harris, Yanzhu Lin et al.· Diabetes, obesity and metabo...· 0 citations
These results support using evolocumab to improve survival in high-risk patients who have not experienced a previous myocardial infarction or stroke, including those with high-risk diabetes without qualifying atherosclerosis with low-density lipoprotein-cholesterol ≥ 90 mg/dl or apolipoprotein B ≥ 80 mg/dl.
Robert P. Giugliano, E. Bohula, A. Bellavia et al.· Circulation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.